HOST-DIRECTED THERAPIES
Developing and testing inhibitors that are active against the enzymes of mycothiol/ergothioneine and Nitrogen metabolism pathways in Mycobacterium tuberculosis as possible new antitubercular drugs. We are also investigating the gene expression and proteomic changes in macrophages infected with pathogenic and non-pathogenic mycobacterial strains, in search of host factors that influence the survival of mycobacteria in macrophages. The ultimate aim is to develop host-directed anti-TB therapeutics.